Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Addition of Rituximab to CHOP-like Chemotherapy Improves Survival in Patients with Primary Mediastinal B-Cell Lymphoma Independent of IPI Risk Category

Katharina Lisenko, MD, Gerrit Dingeldein, Martin Cremer, MD, Mark Kriegsmann, Anthony D. Ho, MD, Michael Rieger, MD, Mathias Witzens-Harig, MD

Blood (2016) 128 (22): 4223.

https://doi.org/10.1182/blood.V128.22.4223.4223

Published: 2016

Journal Articles

T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses

Leopold Sellner, MD, Peter Dreger, MD, Max Schlitt, Henrik Knecht, Dietrich Herrmann, Thomas Reigl, Adam Krejci, Vojtech Bystry, Nikos Darzentas, Michael Rieger, MD, Sascha Dietrich, MD, Thorsten Zenz, MD, Anthony D. Ho, MD, Michael Kneba, Monika Brueggemann

Blood (2015) 126 (23): 3159.

https://doi.org/10.1182/blood.V126.23.3159.3159

Published: 2015

Journal Articles

Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

Mathias Witzens-Harig, MD, Anthony D Ho, MD, Evelyn Kuhnt, Marek Trneny, MD, Michael Rieger, MD, Anders Österborg, MD, PhD, Ruth Pettengell, Robert Stevens, MD, Devinder S Gill, MB ChB, MRCP (UK), FRCPath (Lond), Jan Walewski, Markus Loeffler, Michael Pfreundschuh, MD

Blood (2012) 120 (21): 1612.

https://doi.org/10.1182/blood.V120.21.1612.1612

Published: 2012

Journal Articles

Excellent Long-Term Survival of Patients with Waldenström‘s Macroglobulinemia (WM) treated in Private Oncology Practices and a University hospital with different Treatment Strategies

Manfred Hensel, MD, Jürgen Brust, MD, PhD, Christoph Plöger, MD, Dieter Schuster, MD, Marie-Luise Memmer, Michael Rieger, MD, Lara Hensel, Solveigh Mosthaf, Judith Franz-Werner, MD, Hans-Peter Feustel, MD, Franz Mosthaf, MD, Andreas Karcher, MD, Stefan Fuxius, MD, Anthony D. Ho, MD, Mathias Witzens-Harig, MD

Blood (2011) 118 (21): 2671.

https://doi.org/10.1182/blood.V118.21.2671.2671

Published: 2011

Journal Articles

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Mathias Witzens-Harig, MD, Axel Benner, Michael Rieger, MD, Fabienne McClanahan, MD, Manfred Hensel, MD, Kai Neben, MD, Peter Dreger, MD, Eva Lengfelder, MD, Ingo Schmidt-Wolf, MD, Alwin Krämer, MD, PhD, Anthony D. Ho, MD

Blood (2011) 118 (21): 3700.

https://doi.org/10.1182/blood.V118.21.3700.3700

Published: 2011

Journal Articles

Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)

Paula Cramer, MD, Anna-Maria Fink, MD, Raymonde Busch, Dipl.-Math., Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Natali Pflug, MD, Friederike Schubert, Hartmut Döhner, MD, Michael Rieger, MD, Michael Kneba, MD, PhD, Jiri Mayer, MD, Michael Hallek, MD, Kirsten Fischer, MD

Blood (2011) 118 (21): 2863.

https://doi.org/10.1182/blood.V118.21.2863.2863

Published: 2011

Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW

Blood (2011) 118 (21): 2854.

https://doi.org/10.1182/blood.V118.21.2854.2854

Published: 2011

Journal Articles

Leflunomide Overcomes CD40L/IL-4-Mediated Resistance to Fludarabine-Induced Apoptosis and Effectively Blocks Proliferation of CLL Cells

Sascha Dietrich, Annika Zota, Michael Hess, Michael Rieger, Christof Schweizer, Anthony D. Ho, MD, FRCPC, Peter Dreger, MD, PhD, Thomas Luft

Blood (2010) 116 (21): 1388.

https://doi.org/10.1182/blood.V116.21.1388.1388

Published: 2010

Journal Articles

Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine – Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW

Blood (2010) 116 (21): 920.

https://doi.org/10.1182/blood.V116.21.920.920

Published: 2010

Journal Articles

Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – Final Results of a Multicenter Prospective Randomised Phase II Study.

Mathias Witzens-Harig, Axel Benner, Michael Rieger, Fabienne McClanahan, Manfred Hensel, Kai Neben, Peter Dreger, Eva Lengfelder, Ingo Schmidt-Wolf, Krämer Alwin, Anthony D. Ho

Blood (2009) 114 (22): 1707.

https://doi.org/10.1182/blood.V114.22.1707.1707

Published: 2009

Journal Articles

Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy.

Fabienne McClanahan, MD, Thomas Hielscher, Michael Rieger, MD, Manfred Hensel, MD, PhD, Kai Neben, Jens Hillengass, MD, Klaus Herfarth, MD, PhD, Anthony D. Ho, MD, PhD, Mathias Witzens-Harig, MD

Blood (2009) 114 (22): 2722.

https://doi.org/10.1182/blood.V114.22.2722.2722

Published: 2009

Journal Articles

How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).

Fabienne McClanahan, MD, Thomas Hielscher, Michael Rieger, MD, Manfred Hensel, MD, PhD, Martin Bentz, MD, Ingo Schmidt-Wolf, Andreas Kaebisch, MD, Hans-Jürgen Salwender, Heinz Dürk, Hans Juergen Staiger, MD, Thomas Mandel, MD, Kai Neben, MD, Jens Hillengass, MD, Anthony D. Ho, MD, PhD, Mathias Witzens-Harig, MD

Blood (2009) 114 (22): 2687.

https://doi.org/10.1182/blood.V114.22.2687.2687

Published: 2009

Journal Articles

The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International Trial Group (MInT) Study

Marek Trneny, MD, PhD, Michael Rieger, Anders Osterborg, MD, PhD, Ruth Pettengel, Darrell J White, MD, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Jan Walewski, MD, Evelyn Kuhnt, Markus Loeffler, Michael Pfreundschuh, MD, PhD, Anthony D. Ho, M.D., Ph.D.

Blood (2008) 112 (11): 839.

https://doi.org/10.1182/blood.V112.11.839.839

Published: 2008

Journal Articles

Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease

Thomas Luft, Michael Conzelmann, Axel Benner, Michael Rieger, Michael Hess, Ulrich Strohhaecker, Martin Görner, Ute Hegenbart, Anthony D. Ho, Peter Dreger

Blood (2007) 110 (13): 4535–4542.

https://doi.org/10.1182/blood-2006-10-049817

Published: 2007

Includes: Supplemental data

Journal Articles

Rituximab Improves the Outcome of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Comparison of Different Strategies.

Michael Rieger, MD, Mathias Witzens-Harig, MD, Manfred Hensel, MD, Baerbel Seyfarth, MD, Maike Nickelsen, MD, Michael Kneba, MD, Norbert Schmitz, MD, Anthony D. Ho, MD, Peter Dreger, MD

Blood (2007) 110 (11): 5106.

https://doi.org/10.1182/blood.V110.11.5106.5106

Published: 2007

Journal Articles

Matched Unrelated Donor Stem Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma. A Retrospective Analysis from the EBMT Lymphoma Working Party.

Irit Avivi, MD, PhD, Carme Canals, MD, Goli Taghipour, Jurgen Finke, MD, PhD, Liisa Volin, MD, PhD, Yves Beguin, MD, PhD, Marc Boogaerts, MD, PhD, Charles Crawley, MD, PhD, Michael Rieger, MD, Norbert Schmitz, MD, PhD, Guido Kobbe, MD, PhD, Donald Milligan, MD, PhD, Dietger W. Niederwieser, MD, PhD, Nigel H. Russell, MD, PhD, Rainer Schwerdtfeger, MD, PhD, Anna Sureda, MD

Blood (2006) 108 (11): 3123.

https://doi.org/10.1182/blood.V108.11.3123.3123

Published: 2006

Journal Articles

Favorable Influence of Pretransplant Rituximab but Not of High-Dose Ara-C in Upfront Autologous Stem Cell Transplantation (SCT) for Mantle Cell Lymphoma (MCL).

Michael Rieger, MD, Manfred Hensel, MD, Baerbel Seyfarth, MD, Soeren Sitter, Simona Martin, MD, Rainer Haas, MD, Michael Kneba, MD, Norbert Schmitz, MD, Anthony D. Ho, MD, Peter Dreger, MD

Blood (2005) 106 (11): 2089.

https://doi.org/10.1182/blood.V106.11.2089.2089

Published: 2005

Journal Articles

Outcome of Patients with Primary Mediastinal Large B-Cell Non-Hodgkin’s Lymphomas: A Single Institution Analysis from 1996-2004.

Ute Hegenbart, M.D., Michael Rieger, M.D., Matthias Witzens, M.D., Manfred Hensel, M.D., Anthony D. Ho, M.D.

Blood (2004) 104 (11): 3302.

https://doi.org/10.1182/blood.V104.11.3302.3302

Published: 2004

NARROW

Addition of Rituximab to CHOP-like Chemotherapy Improves Survival in Patients with Primary Mediastinal B-Cell Lymphoma Independent of IPI Risk Category

T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses

Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

Excellent Long-Term Survival of Patients with Waldenström‘s Macroglobulinemia (WM) treated in Private Oncology Practices and a University hospital with different Treatment Strategies

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW

Leflunomide Overcomes CD40L/IL-4-Mediated Resistance to Fludarabine-Induced Apoptosis and Effectively Blocks Proliferation of CLL Cells

Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine – Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW

Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – Final Results of a Multicenter Prospective Randomised Phase II Study.

Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy.

How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).

The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International Trial Group (MInT) Study

Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease

Rituximab Improves the Outcome of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Comparison of Different Strategies.

Matched Unrelated Donor Stem Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma. A Retrospective Analysis from the EBMT Lymphoma Working Party.

Favorable Influence of Pretransplant Rituximab but Not of High-Dose Ara-C in Upfront Autologous Stem Cell Transplantation (SCT) for Mantle Cell Lymphoma (MCL).

Outcome of Patients with Primary Mediastinal Large B-Cell Non-Hodgkin’s Lymphomas: A Single Institution Analysis from 1996-2004.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only